Prospera Insights
Log in
Back to Explorer
PHRecommendable#1 in categoryMODERATE BUYPrimary Pick

SBI Healthcare Opportunities Fund

SBI MF · Tanmaya Desai · benchmarked to Nifty Pharma TRI

Prospera Research Engine unknown · Data as of 1 Jan 1970 · Synced 1 Jan 1970Review date unknown, validation required
Prospera VerdictProspera Recommended

Prospera Score 69, rated Moderate Buy. Ranked 1 in its healthcare peer group and approved as Gate 5 conditional: it is 1.0 points below the Gate 5 threshold of 70 but still a Moderate Buy on every measure, so it is offered with that disclosed. Measured against 8 comparable healthcare funds on AMFI weekly Direct-plan NAVs to 30 Sep 2026 (5.0 years of history): largest fall from a peak 17.4%, 3-year return 23.0% a year. Tanmaya Desai has managed this fund since June 2011.

Final Score69.0
1Y Return21.6%
3Y CAGR22.9%
5Y CAGR18.0%
AUM₹5.4K Cr
Expense Ratio0.76%

Eligibility: All gates passed

Prospera Research

Score Breakdown

13 weighted parameters, exactly as configured in the Research Engine, 8 qualitative (analyst-scored) plus 5 quantitative (formula-derived), summing to a final score out of 100.

Momentum (7% weight)7.5/10
3–6M price+flow vs benchmark
Consistency (10% weight)8.7/10
3Y/5Y quartile rank stability
Portfolio Quality (11% weight)6.0/10
PE, concentration, churn
Fund Mgr Quality (12% weight)6.0/10
Philosophy, communication, style drift
Valuation Risk (10% weight)5.0/10
Portfolio PE/PB vs category avg
Sector Tailwinds (9% weight)6.0/10
Policy/macro drivers 12-18M
Downside Protection (8% weight)8.7/10
Max DD, Sortino, bear markets
Outperformance Prob. (8% weight)7.0/10
Analyst 12M alpha probability
Mgr Tenure Score (8% weight)8.0/10
Years managing fund → 1-10 score
AMC Quality Score (6% weight)7.0/10
Research depth, AUM scale, compliance
AUM Trend Score (5% weight)9.0/10
Growing=9, Stable=6, Declining=3
Expense Ratio Score (4% weight)5.0/10
Inverse ER — lower cost = higher score
Thesis Strength (2% weight)6.0/10
Analyst 12-24M thesis conviction
Final Score69.0/100
Prospera Research

Why This Fund

Stance: max allocation

Prospera Score 69, rated Moderate Buy. Ranked 1 in its healthcare peer group and approved as Gate 5 conditional: it is 1.0 points below the Gate 5 threshold of 70 but still a Moderate Buy on every measure, so it is offered with that disclosed. Measured against 8 comparable healthcare funds on AMFI weekly Direct-plan NAVs to 30 Sep 2026 (5.0 years of history): largest fall from a peak 17.4%, 3-year return 23.0% a year. Tanmaya Desai has managed this fund since June 2011.

Prospera Research

Analyst Write-Up

A full analyst write-up hasn't been published for this fund yet, only shortlisted funds at the review stage get one. The score breakdown and performance data above are still real and current.

Prospera Research

Risk-Adjusted Performance

3Y AlphaN/A
5Y AlphaN/A
Max Drawdown17.4%
Sharpe (3Y)1.18
Sortino (3Y)1.83
Beta0.67
Alpha Consistency77%
Prospera Research

AMC & Manager Intelligence

SBI MF
AA — TIER 1
35-analyst research team · Clean — minor queries

Largest AMC by AUM. Government backing provides distribution moat. Research quality slightly below ICICI/HDFC but improving. Compliance record has had minor queries (no enforcement). Strong in debt; improving in equity.